Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib

Patients with metastatic colorectal cancer (mCRC) carrying BRAFV600E mutation have worse response to chemotherapy and poor prognosis. The BRAFV600E inhibitor vemurafenib has shown modest efficacy as monotherapy in BRAF-mutated mCRC due to the development of resistance. The aim of this study was to c...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Iris Car, Antje Dittmann, Marko Klobučar, Petra Grbčić, Sandra Kraljević Pavelić, Mirela Sedić
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2023-04-01
Edice:	Biology
Témata:	BRAFV600E colon cancer secretome BRAF inhibition vemurafenib DNA replication
On-line přístup:	https://www.mdpi.com/2079-7737/12/4/608
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!